Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma

Annals of Oncology

Volumn 21, Issue 8, 2009, Pages 1612-1617

  Kawai, Y ^a   Sakano, S ^a   Suehiro, Y ^a   Okada, T ^a   Korenaga, Y ^a   Hara, T ^a   Naito, K ^a   Matsuyama, H ^a   Hinoda, Y ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

COBRA; Kidney cancer; Survival; Tumor suppressor gene

Indexed keywords

BISULFITE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; CPG ISLAND; FEMALE; HUMAN; JAPANESE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN METHYLATION; RESTRICTION MAPPING; SEQUENCE ANALYSIS;

EID: 77954615960     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp577     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Storkel S, Eble JN, Adlakha K et al. Classification of renal cell carcinoma: workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997; 80: 987-989.
3. Kok K, Naylor SL, Buys CH. Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv Cancer Res 1997; 71: 27-92.
4. Thrash-Bingham CA, Greenberg RE, Howard S et al. Comprehensive allelotyping of human renal cell carcinomas using microsatellite DNA probes. Proc Natl Acad Sci U S A 1995; 92: 2854-2858.
5. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7: 85-90.
6. Herman JG, Latif F, Weng Y et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994; 91: 9700-9704.
7. Dammann R, Li C, Yoon JH et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000; 25: 315-319.
8. Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 2005; 65: 3497-3508.
9. Song MS, Song SJ, Ayad NG et al. The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 2004; 6: 129-137.
10. Dallol A, Cooper WN, Al-Mulla F et al. Depletion of the Ras association domain family 1, isoform A-associated novel microtubule-associated protein, C19ORF5/MAP1S, causes mitotic abnormalities. Cancer Res 2007; 67: 492-500.
11. Dallol A, Agathanggelou A, Tommasi S et al. Involvement of the RASSF1A tumor suppressor gene in controlling cell migration. Cancer Res 2005; 65: 7653-7659.
12. Tommasi S, Dammann R, Zhang Z et al. Tumor susceptibility of Rassf1a knockout mice. Cancer Res 2005; 65: 92-98.
13. Dreijerink K, Braga E, Kuzmin I et al. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci U S A 2001; 98: 7504-7509.
14. Yoon JH, Dammann R, Pfeifer GP. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer 2001; 94: 212-217.
15. Gonzalgo ML, Yegnasubramanian S, Yan G et al. Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. Clin Cancer Res 2004; 10: 7276-7283.
16. Agathanggelou A, Honorio S, Macartney DP et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001; 20: 1509-1518.
17. Byun DS, Lee MG, Chae KS et al. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res 2001; 61: 7034-7038.
18. Liu L, Yoon JH, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 2002; 21: 6835-6840.
19. Schagdarsurengin U, Wilkens L, Steinemann D et al. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 2003; 22: 1866-1871.
20. Yates DR, Rehman I, Abbod MF et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res 2007; 13: 2046-2053.
21. Kim DH, Kim JS, Ji YI et al. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res 2003; 63: 3743-3746.
22. Wang Y, Yu Z, Wang T et al. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer 2007; 56: 289-294.
23. Muller HM, Widschwendter A, Fiegl H et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 2003; 63: 7641-7645.
24. Yanagawa N, Tamura G, Oizumi H et al. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer 2007; 58: 131-138.
25. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994; 22: 2990-2997.
26. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997; 25: 2532-2534.
27. Shen L, Kondo Y, Hamilton SR et al. P14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53. Gastroenterology 2003; 124: 626-633.
28. Kondo Y, Shen L, Yan PS et al. Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation. Proc Natl Acad Sci U S A 2004; 101: 7398-7403.
29. Peters I, Rehmet K, Wilke N et al. RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. Mol Cancer 2007; 6: 49.
30. Akino K, Toyota M, Suzuki H et al. The Ras effector RASSF2 is a novel tumorsuppressor gene in human colorectal cancer. Gastroenterology 2005; 129: 156-169.
31. Costa VL, Henrique R, Ribeiro FR et al. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer 2007; 7: 133.
32. Tezval H, Merseburger AS, Matuschek I et al. RASSF1A protein expression and correlation with clinicopathological parameters in renal cell carcinoma. BMC Urol 2008; 8: 12.
33. Suehiro Y, Wong CW, Chirieac LR et al. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res 2008; 14: 2560-2569.